Therefore, VEGF-mediated signaling has become one of the most promising antiangiogenic therapeutic targets in oncology for clinical treatment of human cancers and metastasis [31], especially when it is not difficult to find acquired or intrinsic therapy resistance associated with anti-VEGF monotherapeutic approaches. This evidence concerns the gene VEGFA and cancer.